• Mitoxantrone Assays for ABCG2 Resistance

  2026-09-14

  Mitoxantrone BA2039 supports a practical workflow that connects topoisomerase II inhibition, intracellular drug exposure, ABCG2-mediated resistance, and apoptosis. This guide translates the marein–ABCG2 findings into reproducible viability, accumulation, combination, and troubleshooting strategies for oncology and carefully bounded antiviral research.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-13

  This 2024 Journal of Ethnopharmacology study integrates network pharmacology with cellular and mouse models to examine how Shenqi Fuzheng injection affects glioma growth and migration. Its main contribution is the identification of the SRC/PI3K/AKT pathway as a candidate mechanistic axis linked to cell-cycle arrest, reduced migration, and slower tumor development.

• Ceftazidime: From Spectrum to Resistance Assays

  2026-09-12

  Ceftazidime is a third-generation cephalosporin with distinctive value in Pseudomonas aeruginosa and Gram-negative bacterial infection research. This guide connects its mechanism and handling requirements with genomic, plasmid-transfer, and susceptibility findings from a 2025 CREC study to improve assay interpretation.

• How Mixing Shapes mRNA LNP Performance

  2026-09-11

  This Nature Communications study isolates primary mixing as a major determinant of mRNA lipid nanoparticle physicochemical properties and biological performance. By comparing ten mixing approaches under otherwise controlled formulation conditions, it shows why manually prepared or laminar-flow particles may not predict products made with turbulent-flow equipment at manufacturing scale.

• SM-102: Reliable LNP and Cell Assay Workflows

  2026-09-11

  This scenario-based guide explains how SM-102 (SKU C1042) can support controlled lipid nanoparticle formulation and more interpretable downstream cell viability, proliferation, and cytotoxicity assays. It covers solvent compatibility, formulation controls, literature-based comparison, and practical supplier-selection criteria.

• SIRT1/2 Inhibitor IV: OGD/R Assay Guide

  2026-09-10

  Use SIRT1/2 Inhibitor IV (cambinol) to interrogate how SIRT1/2 activity connects metabolism, lactylation, STAT3 transport, acetylation, and cell survival. This workflow separates reference-supported biology from practical starting conditions for astrocyte OGD/R, cancer-cell apoptosis, and xenograft studies.

• Separating Growth Arrest from Cancer Cell Death

  2026-09-10

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different components of drug response. The framework supports more interpretable cancer assays by separating proliferative arrest from actual cell killing and by accounting for differences in response timing.

• Cabozantinib Workflows for RCC Signaling Studies

  2026-09-09

  Build sharper RCC and MTC experiments with Cabozantinib (XL184) by separating acute kinase suppression from chronic signaling adaptation. This workflow combines phosphoproteomics, migration, invasion, and endothelial assays to reveal both treatment response and resistance-associated phenotypes.

• DOT1L Inhibition Reprograms Immunity in Myeloma

  2026-09-09

  The reference study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and shows that its inhibition activates type I interferon and STING-associated innate immune signaling. Importantly, DOT1L inhibition enhanced lenalidomide responses by increasing interferon-regulated genes and suppressing IRF4-MYC signaling, providing a mechanistic basis for combination research.

• Biotin-HPDP for Reversible Thiol Labeling

  2026-09-08

  Biotin-HPDP is a sulfhydryl-reactive reagent for reversible labeling of accessible protein thiols. Its pyridyl disulfide chemistry connects biotin affinity capture with applications such as protein biotinylation for affinity purification and detection of S-nitrosylated proteins.

• Anlotinib in Desmoplastic Small Round Cell Tumor

  2026-09-08

  This case report describes radiographic regression of metastatic intra-abdominal desmoplastic small round cell tumor after anlotinib treatment, with fatigue and hypertriglyceridemia as manageable toxicities. Its main contribution is hypothesis-generating clinical evidence for a multi-target tyrosine kinase inhibitor in a rare sarcoma lacking standardized systemic therapy.

• Sunitinib: Multi-Targeted RTK Inhibitor

  2026-09-07

  Sunitinib is an orally bioavailable, multi-targeted receptor tyrosine kinase inhibitor that blocks VEGFR, PDGFR, KIT, and RET signaling. Its research value includes tumor angiogenesis assays, apoptosis induction in renal cell carcinoma, and cell cycle arrest at G0/G1 phase, while combination findings remain preclinical.

• D-Luciferin for Cotton Defense Reporter Assays

  2026-09-07

  Translate the GoPGF–JAVL feedback model into quantitative luciferase reporter experiments, while using the same substrate for in vivo bioluminescence imaging and tumor cell tracking. This guide combines assay design, practical dosing ranges, fresh-solution handling, and troubleshooting for reproducible firefly luciferase workflows.

• WRN–MMR Synthetic Lethality in MSI Colon Cancer

  2026-09-05

  This PNAS study explains why mismatch repair-deficient, microsatellite-instable colorectal cancer cells depend on Werner helicase: WRN loss activates a p53–PUMA apoptotic program. Genetic depletion and pharmacologic RecQ helicase inhibition suppressed MSI tumor growth in cell and xenograft models, supporting WRN as a context-dependent therapeutic target in p53-wild-type disease.

• In Vitro Drug Response Metrics and Timing

  2026-09-04

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an anticancer response. This framework helps researchers design assays that resolve response magnitude, biological composition, and timing rather than treating a single viability endpoint as a complete measure of drug activity.

7423 records 1/495 page Next 12345 下5页 Last page